Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Mechanism-based influenza neuraminidase inhibitors as antivirals to combat flu infections

Objective

Influenza neuraminidases are the primary target for anti-influenza small molecule drugs and are retaining glycosidases that form a transient covalent intermediate during substrate hydrolysis. Oseltamivir (Tamiflu) and Zanamivir (Relenza), the two small-molecule anti-influenza drugs used primarily for early onset treatment of flu infections, inhibit influenza neuraminidases competitively (and thus reversibly). The AziFlu ERC PoC proposal is rooted in our finding that N-acyl Oseltamivir aziridines, or Aziflus, inhibit influenza neuraminidase covalently. They block viral outgrowth in an infected cell model. Our compounds are at least as potent as Oseltamivir. Rather than temporarily disabling influenza neuraminidases, our technology acts in an irreversible, permanent, manner. Our drug candidates are selective for influenza neuraminidases over human neuraminidases, and we propose they may be more effective than existing drugs and may also find use as prophylactics and to treat later disease stages. The AziFlu program will develop our mechanism-based influenza neuraminidase inhibition technology and take the first steps to create a start-up company for bringing the technology to market. To strengthen our scientific case (experimental development, A), we will (A-I) optimise our leads by the synthesis and biochemical evaluation of comprehensive sets of focused analogues; (A-II) design a synthetic route to prepare gram-scale quantities of selected leads; and (A-III) develop assays for in vitro and in vivo target inhibition efficacy, target engagement, and viral outgrowth studies. To prepare for the establishment of a spin-out biotech company (business development, B) to take our leads towards the clinic we will (B-IV) strengthen our intellectual property (IP) position; (B-V) analyse the anti-influenza drug market; and (B-VI) create a start-up biotech company to which the IP will be transferred.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

UNIVERSITEIT LEIDEN
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 150 000,00
Address
RAPENBURG 70
2311 EZ Leiden
Netherlands

See on map

Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Beneficiaries (1)

My booklet 0 0